Tyrosine kinase inhibitorFDA-approvedSecond-line
Stivarga
Generic name: regorafenib
How it works
Regorafenib blocks multiple enzymes involved in tumor growth and angiogenesis, including VEGFR, PDGFR, and RAF.
Cancer types
Colorectal Cancer— All patients
Efficacy
Studies show that regorafenib can improve overall survival in patients with metastatic colorectal cancer who have received prior therapy.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Researchers Identify Potential Biomarker for Colorectal Cancer Treatment | Colorectal Cancer | phase-2 | — | Source → |
| Regorafenib Dosage May Vary by Body Weight in Colorectal Cancer Patients | Colorectal Cancer | observational | Among the light-weight patients, higher average dose was associated with shorter OS (IPTW adjusted HR=1.21, 95% CI 1.05 - 1.39) | Source → |
| Regorafenib Therapy for Metastatic Colorectal Cancer | Colorectal Cancer | phase-2 | The median progression-free survival was 4 ± 0.2 months, and the median overall survival was 9 ± 1.2 months. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.